Previous studies found that the upregulation of ENO1 was positively correlated with progression and poor prognosis in breast cancer, prostate cancer, thyroid carcinoma, hepatocellular carcinoma, cholangiocarcinoma, neuroblastoma, neuroendocrine tumors, lung cancer, and pancreatic cancer (4, 9–13). Here, ENO1 is linked to cholangiocarcinoma.